Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

MET/EGFR Combo Effective for Advanced NSCLC

October 17th 2017

The combination of osimertinib and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non–small cell lung cancer.

Emerging Therapies for Nonsquamous NSCLC

October 17th 2017

Consolidation Immunotherapy for Locally Advanced NSCLC

October 17th 2017

NSCLC: Promising Molecular Targets

October 17th 2017

Changing Treatment Paradigm for BRAF-Mutant NSCLC

October 17th 2017

Second-Line Brigatinib for ALK-Rearranged NSCLC

October 17th 2017

ALEX Trial: Frontline Therapy for ALK-Rearranged NSCLC

October 17th 2017

Upfront Therapy for ALK/ROS1-Rearranged NSCLC

October 17th 2017

EGFR-Positive NSCLC: Treatment at Progression

October 17th 2017

Managing CNS Metastases in EGFR-Positive NSCLC

October 17th 2017

Osimertinib as Frontline Therapy for EGFR-Positive NSCLC

October 17th 2017

NSCLC: Immunotherapy Beyond Progression

October 17th 2017

Duration of Immunotherapy for NSCLC

October 17th 2017

NSCLC: Approach for Progression on Chemotherapy

October 17th 2017

Reliability of PD-L1 Testing in NSCLC

October 17th 2017

Upfront Immunotherapy for NSCLC

October 17th 2017

FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC

October 17th 2017

The FDA has granted a priority review to a supplemental biologics license application for durvalumab (Imfinzi) for the treatment of patients with stage III, unresectable NSCLC.

Dacomitinib Stands Out in EGFR-Mutated Subtype Response

October 17th 2017

Second-generation EGFR inhibitor dacomitinib showed clear superiority over first-generation TKI gefitinib (Iressa) in a comparison of performance in EGFR mutation subtypes exon 19 deletion and L858R in advanced NSCLC.

Ramucirumab Associated With OS Benefit in Aggressive NSCLC

October 17th 2017

Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival benefit versus placebo plus docetaxel in patients with advanced NSCLC whose disease rapidly progressed on first-line therapy,

Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC

October 16th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).